Clinical trial · no report yet · Phase 2
ASTEROID
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)
- NCT03446547 ↗
- Completed
- Vastra Gotaland Region
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An Open Label Randomized Phase II Trial With Durvalumab Following Stereotactic Body Radiotherapy (SBRT) in Patients With Stage I Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- NSCLC, Stage I
- Interventions
- Durvalumab
- Arms
- Arm A · No intervention
- Arm B · Experimental
- Enrollment
- 106
- Primary outcomes
- TTP
- Sponsor
- Vastra Gotaland Region with AstraZeneca
- Start
- Dec 4, 2017
- Primary completion
- Oct 1, 2025
- Results posted
- No
- Registry record
- NCT03446547 · updated Apr 14, 2026